表紙:肛門癌の世界市場:薬剤タイプ別(フルオロウラシル、シスプラチン、カルボプラチン、その他)、癌の種類別、治療タイプ別、流通チャネル別、地域別- 規模、シェア、展望、機会分析(2021年~2028年)
市場調査レポート
商品コード
1035436

肛門癌の世界市場:薬剤タイプ別(フルオロウラシル、シスプラチン、カルボプラチン、その他)、癌の種類別、治療タイプ別、流通チャネル別、地域別- 規模、シェア、展望、機会分析(2021年~2028年)

Anal Cancer Market, by Drug Type (Fluorouracil, Cisplatin, Carboplatin, and Others ), by Cancer Type, by Treatment Type, by Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028

出版日: | 発行: Coherent Market Insights | ページ情報: 英文 154 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.11円
肛門癌の世界市場:薬剤タイプ別(フルオロウラシル、シスプラチン、カルボプラチン、その他)、癌の種類別、治療タイプ別、流通チャネル別、地域別- 規模、シェア、展望、機会分析(2021年~2028年)
出版日: 2021年10月19日
発行: Coherent Market Insights
ページ情報: 英文 154 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 目次
概要

肛門癌は、肛門管にできるまれなタイプの癌です。肛門管とは、肛門と直腸の間にある長さ約1~1.5インチの短い管で、ここを通って便が体外に排出されます。肛門癌に関連する症状としては、肛門または直腸からの出血、肛門付近のしこり、肛門周辺の痛み、肛門のかゆみ、肛門からの分泌物、腸内環境の変化などがあります。肛門癌は、ヒトパピローマウイルス(HPV)の感染、複数の性的パートナーの存在、受容的な肛門性交(アナルセックス)、過度の喫煙、膣癌、子宮頸癌、外陰癌の病歴など、さまざまな危険因子によって引き起こされます。また、臓器移植やヒト免疫不全ウイルス(HIV)など、免疫力が低下する病気や状態にある免疫不全患者も対象となります。

肛門癌や性感染症の発生率の増加、肛門癌治療のための新規治療薬開発のための研究開発活動の活発化、市場で活動する主要企業による買収や提携などの無機的な成長戦略の採用の増加などが、予測期間における世界の肛門癌市場の成長を促進する主な要因となります。

当レポートでは、世界の肛門癌市場について調査分析し、促進要因、抑制要因、COVID-19の影響、薬剤タイプ別、癌の種類別、治療タイプ別、流通チャネル別、地域別市場情報、企業プロファイルを提供しています。

目次

第1章 調査目的・前提条件

第2章 市場の展望

  • レポートの説明
    • 市場の定義と範囲
  • エグゼクティブサマリー
    • 市場内訳:薬剤タイプ別
    • 市場内訳:癌の種類別
    • 市場内訳:治療タイプ別
    • 市場内訳:流通チャネル別
    • 市場内訳:地域別
  • Coherent Opportunity Map(COM)

第3章 市場力学、規制、および動向分析

  • 市場力学
    • 促進要因
    • 抑制要因
    • 市場機会
  • 影響分析
  • パイプライン分析
  • PEST分析
  • 規制シナリオ
  • 市場動向
  • 主なハイライト
  • 償還シナリオ
  • 合併と買収

第4章 肛門癌の世界市場-COVID-19パンデミックの影響

  • 経済的影響
  • 臨床試験と医薬品開発への影響
  • 政府のイニシアチブ

第5章 肛門癌の世界市場:薬剤タイプ別(2017ー2028年(100万米ドル))

  • イントロダクション
  • フルオロウラシル
  • シスプラチン
  • カルボプラチン
  • その他(その他には、ミトマイシン、オキサリプラチン、ドセタキセル、ロイコボリンなどが含まれます)

第6章 肛門癌の世界市場:癌の種類別(2017ー2028年(100万米ドル))

  • イントロダクション
  • 上皮内癌
  • 扁平上皮癌
  • 黒色腫
  • 腺癌
  • 基底細胞癌

第7章 肛門癌の世界市場:治療タイプ別(2017ー2028年(100万米ドル))

  • イントロダクション
  • 化学療法
  • 手術
  • 放射線治療
  • 免疫療法

第8章 肛門癌の世界市場:流通チャネル別(2017ー2028年(100万米ドル))

  • イントロダクション
  • 病院とクリニック
  • 調査&学術機関
  • 介護センター
  • 薬局

第9章 肛門癌の世界市場:地域別(2017ー2028年(100万米ドル))

  • イントロダクション
  • 北米
  • ラテンアメリカ
  • 欧州
  • アジア太平洋
  • 中東
  • アフリカ

第10章 競合情勢

  • ヒートマップ分析
  • 市場シェア分析
    • Advaxis, Inc.
    • ORYX GmbH and Co. KG
    • Eli Lilly and Company
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Onconova Therapeutics
    • BioMimetix JV, LLC
    • Bayer AG
    • Spectrum Pharmaceuticals Inc.
    • Global BioPharma Inc.
    • Amgen Inc.
    • Atara Biotherapeutics Inc.
    • ISA Pharmaceuticals
    • Takeda Pharmaceutical Company Limited
    • Ono Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Johnson &Johnson Private Limited
  • アナリストの見解

第11章 セクション

目次
Product Code: CMI4701

Anal cancer is a rare type of cancer in the anal canal. The anal canal is a short tube, about 1-1½ inches long between anal opening and rectum through which stool passes out of the human body. Some of the symptoms associated with anal cancer include anal or rectum bleeding, lump near anus, pain around the anus, itching in the anus, discharge from the anus, changes in bowel habits, and others. Anal cancer can be caused due to a number of risk factors such as human papillomavirus (HPV) infection, having multiple sexual partners, indulging in receptive anal intercourse (anal sex), excessive smoking, medical history of vaginal, cervical or vulvar cancers. Moreover, immune-compromised patients who have a disease or condition which causes weakening of immune system such as organ transplant, human immunodeficiency virus (HIV), and others.

Market Dynamics

The increasing incidence of anal cancer and sexually transmitted diseases, rising research and development activities for the development of novel therapeutics for the treatment of anal cancer, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global anal cancer market over the forecast period.

For instance, according to data provided by the Cancer Research U.K. in 2018, around 1,500 new cases of anal cancer are reported every year in the U.K, i.e. four new anal cancer cases daily. The same source also states that the incidence rate of anal cancer in the U.K. is highest in elderly people of age 90 and above.

Key features of the study:

  • This report provides in-depth analysis of the global anal cancer market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021-2028), considering 2020 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global anal cancer market based on the following parameters - company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Advaxis, Inc., ORYX GmbH and Co. KG, Eli Lilly and Company, Merck KGaA, F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Onconova Therapeutics, BioMimetix JV, LLC, Bayer AG, Spectrum Pharmaceuticals Inc., Global BioPharma Inc., Amgen Inc., Atara Biotherapeutics Inc., ISA Pharmaceuticals, Takeda Pharmaceutical Company Limited, Ono Pharmaceutical Co., Ltd., Sun Pharmaceutical Industries Ltd., Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Sanofi, and Johnson & Johnson Private Limited
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global anal cancer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global anal cancer market

Detailed Segmentation:

  • Global Anal Cancer Market, By Drug Type:
    • Fluorouracil
    • Cisplatin
    • Carboplatin
    • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
  • Global Anal Cancer Market, By Cancer Type:
    • Carcinoma In-situ
    • Squamous Cell Carcinoma
    • Melanoma
    • Adenocarcinoma
    • Basal Cell Carcinoma
  • Global Anal Cancer Market, By Treatment Type:
    • Chemotherapy
    • Surgery
    • Radiation Therapy
    • Immunotherapy
  • Global Anal Cancer Market, By Distribution Channel:
    • Hospitals & Clinics
    • Research & Academic Institutes
    • Long-term Care Centers
    • Pharmacies
  • Global Anal Cancer Market, By Region:
    • North America
      • By Drug Type
      • Fluorouracil
      • Cisplatin
      • Carboplatin
      • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
      • Carcinoma In-situ
      • Squamous Cell Carcinoma
      • Melanoma
      • Adenocarcinoma
      • Basal Cell Carcinoma
      • By Treatment Type
      • Chemotherapy
      • Surgery
      • Radiation Therapy
      • Immunotherapy
      • By Distribution Channel
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Long-term Care Centers
      • Pharmacies
      • By Country
      • U.S.
      • Canada
    • Latin America
      • By Drug Type
      • Fluorouracil
      • Cisplatin
      • Carboplatin
      • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
      • Carcinoma In-situ
      • Squamous Cell Carcinoma
      • Melanoma
      • Adenocarcinoma
      • Basal Cell Carcinoma
      • By Treatment Type
      • Chemotherapy
      • Surgery
      • Radiation Therapy
      • Immunotherapy
      • By Distribution Channel
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Long-term Care Centers
      • Pharmacies
      • By Country
      • Brazil
      • Mexico
      • Argentina
      • Rest of Latin America
    • Europe
      • By Drug Type
      • Fluorouracil
      • Cisplatin
      • Carboplatin
      • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
      • Carcinoma In-situ
      • Squamous Cell Carcinoma
      • Melanoma
      • Adenocarcinoma
      • Basal Cell Carcinoma
      • By Treatment Type
      • Chemotherapy
      • Surgery
      • Radiation Therapy
      • Immunotherapy
      • By Distribution Channel
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Long-term Care Centers
      • Pharmacies
      • By Country
      • Germany
      • U.K.
      • France
      • Italy
      • Spain
      • Russia
      • Rest of Europe
    • Asia Pacific
      • By Drug Type
      • Fluorouracil
      • Cisplatin
      • Carboplatin
      • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
      • Carcinoma In-situ
      • Squamous Cell Carcinoma
      • Melanoma
      • Adenocarcinoma
      • Basal Cell Carcinoma
      • By Treatment Type
      • Chemotherapy
      • Surgery
      • Radiation Therapy
      • Immunotherapy
      • By Distribution Channel
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Long-term Care Centers
      • Pharmacies
      • By Country
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • ASEAN
      • Rest of Asia Pacific
    • Middle East
      • By Drug Type
      • Fluorouracil
      • Cisplatin
      • Carboplatin
      • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
      • Carcinoma In-situ
      • Squamous Cell Carcinoma
      • Melanoma
      • Adenocarcinoma
      • Basal Cell Carcinoma
      • By Treatment Type
      • Chemotherapy
      • Surgery
      • Radiation Therapy
      • Immunotherapy
      • By Distribution Channel
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Long-term Care Centers
      • Pharmacies
      • By Country
      • GCC
      • Israel
      • Rest of Middle East
    • Africa
      • By Drug Type
      • Fluorouracil
      • Cisplatin
      • Carboplatin
      • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
      • By Cancer Type
      • Carcinoma In-situ
      • Squamous Cell Carcinoma
      • Melanoma
      • Adenocarcinoma
      • Basal Cell Carcinoma
      • By Treatment Type
      • Chemotherapy
      • Surgery
      • Radiation Therapy
      • Immunotherapy
      • By Distribution Channel
      • Hospitals & Clinics
      • Research & Academic Institutes
      • Long-term Care Centers
      • Pharmacies
      • By Country/Region
      • South Africa
      • Central Africa
      • North Africa
  • Company Profiles
    • Advaxis, Inc.*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • ORYX GmbH and Co. KG
    • Eli Lilly and Company
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Onconova Therapeutics
    • BioMimetix JV, LLC
    • Bayer AG
    • Spectrum Pharmaceuticals Inc.
    • Global BioPharma Inc.
    • Amgen Inc.
    • Atara Biotherapeutics Inc.
    • ISA Pharmaceuticals
    • Takeda Pharmaceutical Company Limited
    • Ono Pharmaceutical Co., Ltd.
    • Sun Pharmaceutical Industries Ltd.
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Johnson & Johnson Private Limited

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snippet, By Drug Type
    • Market Snippet, By Cancer Type
    • Market Snippet, By Treatment Type
    • Market Snippet, By Distribution Channel
    • Market Snippet, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Pipeline Analysis
  • PEST Analysis
  • Regulatory Scenario
  • Market Trends
  • Key Highlights
  • Reimbursement Scenario
  • Mergers & Acquisitions

4. Global Anal Cancer Market - Impact of Coronavirus (Covid-19) Pandemic

  • Economic Impact
  • Impact on Clinical Trials and Drug Development
  • Government Initiatives

5. Global Anal Cancer Market, By Drug Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Fluorouracil
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Cisplatin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Carboplatin
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Others (Others include Mitomycin, Oxaliplatin, Docetaxel, Leucovorin, etc.)
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

6. Global Anal Cancer Market, By Cancer Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Carcinoma In-situ
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Squamous Cell Carcinoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Melanoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Adenocarcinoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Basal Cell Carcinoma
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

7. Global Anal Cancer Market, By Treatment Type, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Chemotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Surgery
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Radiation Therapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Immunotherapy
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

8. Global Anal Cancer Market, By Distribution Channel, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, 2018 - 2028
    • Segment Trends
  • Hospitals & Clinics
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Research & Academic Institutes
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Long-term Care Centers
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)
  • Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Mn)

9. Global Anal Cancer Market, By Region, 2017 - 2028, (US$ Mn)

  • Introduction
    • Market Share Analysis, By Region, 2021 and 2028 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2028
  • North America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Cancer Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • U.S.
    • Canada
  • Latin America
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Cancer Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Cancer Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Cancer Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Cancer Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Country, 2017 - 2028, (US$ Mn)
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • Market Size and Forecast, By Drug Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Cancer Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Treatment Type, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Distribution Channel, 2017 - 2028, (US$ Mn)
    • Market Size and Forecast, By Region/Country, 2017 - 2028, (US$ Mn)
    • South Africa
    • Central Africa
    • North Africa

10. Competitive Landscape

  • Heat Map Analysis
  • Market Share Analysis
    • Advaxis, Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • ORYX GmbH and Co. KG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Eli Lilly and Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Merck KGaA
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • F. Hoffmann-La Roche Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • GlaxoSmithKline plc
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Onconova Therapeutics
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • BioMimetix JV, LLC
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bayer AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Spectrum Pharmaceuticals Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Global BioPharma Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Amgen Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Atara Biotherapeutics Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • ISA Pharmaceuticals
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Takeda Pharmaceutical Company Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Ono Pharmaceutical Co., Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sun Pharmaceutical Industries Ltd.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Bristol-Myers Squibb Company
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Novartis AG
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Pfizer Inc.
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Sanofi
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
    • Johnson & Johnson Private Limited
    • Company Overview
    • Product Portfolio
    • Financial Overview
    • Key Highlights
    • Market Strategies
  • Analyst Views

11. Section

  • References
  • Research Methodology
  • About us and Sales Contact